Peking Univ. NSD3 compound A8

Peking Univ. NSD3 compound A8: sourced facts only. name: "Herein, we report the rational design, synthesis, and comprehensive biological evaluation of a series of NSD3 inhibitors, culminating in the identification of compound A8, which demonstrates potent inhibitory activity against NSD3 and LUSC cell proliferation, with an IC50 of 0.355 μM in NCI-H1703 cells, and less toxicity to non-cancerous HEK293T cells." [PMID:40010269]; target: "Herein, we report the rational design, synthesis, and comprehensive biological evaluation of a series of NSD3 inhibitors, culminating in the identification of compound A8, which demonstrates potent inhibitory activity against NSD3 and LUSC cell proliferation, with an IC50 of 0.355 μM in NCI-H1703 cells, and less toxicity to non-cancerous HEK293T cells." [PMID:40010269]; developer: "State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China." [PMID:40010269]; stage: "Notably, compound A8 displayed favorable pharmacokinetic properties and efficaciously suppressed tumor growth in an NCI-H520 xenograft mouse model without observable adverse effects." [PMID:40010269]